Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H12N2O4 |
Molecular Weight | 224.2133 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O
InChI
InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N
InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1
Molecular Formula | C10H12N2O4 |
Molecular Weight | 224.2133 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00649Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00649
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,020413s020lbl.pdf
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated. Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Stavudine is used for the treatment of human immunovirus (HIV) infections. Stavudine is sold under the brand name Zerit among others.
Originator
Sources: http://adisinsight.springer.com/drugs/800001691
Curator's Comment: # Bristol-Myers Squibb; Yale University; Yamasa Corporation
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL378 |
1.9 µM [IC50] | ||
Target ID: CHEMBL247 |
0.0083 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Zerit Approved UseZERIT (stavudine), in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection Launch Date1994 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
228 ng/mL |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
STAVUDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
536 ng/mL |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
STAVUDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1966 ng × h/mL |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
STAVUDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2568 ng × h/mL |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
STAVUDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% |
100 mg 1 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
STAVUDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
100% |
40 mg 2 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
STAVUDINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Other AEs: Abdominal pain, Asthenia... Other AEs: Abdominal pain (19%) Sources: Asthenia (18%) Headache (25%) Diarrhea (34%) Dyspepsia (12%) Nausea (24%) Vomiting (12%) Lipodystrophy (6%) Arthralgia (6%) Myalgia (4%) Abnormal dreams (19%) Depressive disorders (13%) Dizziness (26%) Insomnia (22%) Neuropathy (13%) Paresthesia (12%) Cough increased (9%) Rhinitis (11%) Rash (35%) Skin discoloration (<1%) |
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Headache, Diarrhea... Other AEs: Headache (54 patients) Sources: Diarrhea (50 patients) Neuropathy peripheral (52 patients) Rash (40 patients) Nausea and vomiting (39 patients) |
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Nausea, Diarrhea... Other AEs: Nausea (43 patients) Sources: Diarrhea (34 patients) Headache (25 patients) Rash (18 patients) Vomiting (18 patients) Neuropathy peripheral (8 patients) |
40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Nausea, Diarrhea... Other AEs: Nausea (53 patients) Sources: Diarrhea (45 patients) Headache (46 patients) Rash (30 patients) Vomiting (30 patients) Neuropathy peripheral (21 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rhinitis | 11% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Dyspepsia | 12% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Paresthesia | 12% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Vomiting | 12% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Depressive disorders | 13% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Neuropathy | 13% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Asthenia | 18% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Abdominal pain | 19% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Abnormal dreams | 19% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Insomnia | 22% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Nausea | 24% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Headache | 25% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Dizziness | 26% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Diarrhea | 34% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Rash | 35% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Myalgia | 4% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Arthralgia | 6% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Lipodystrophy | 6% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Cough increased | 9% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Skin discoloration | <1% | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 36.5 |
Nausea and vomiting | 39 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Rash | 40 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Diarrhea | 50 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Neuropathy peripheral | 52 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Headache | 54 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Rash | 18 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Vomiting | 18 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Headache | 25 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Diarrhea | 34 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Nausea | 43 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Neuropathy peripheral | 8 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Neuropathy peripheral | 21 patient | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Rash | 30 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Vomiting | 30 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Diarrhea | 45 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Headache | 46 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Nausea | 53 patients | 40 mg 2 times / day multiple, oral Recommended Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
unlikely | ||||
weak | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/18310046/ |
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/021453_S000_Zerit_BioPharmR.pdf#page=11 Page: 11.0 |
no | |||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine. | 1999 Mar |
|
cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade. | 1999 May 6 |
|
cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. | 1999 May 6 |
|
Didanosine-induced hepatitis. | 2000 Aug |
|
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. | 2000 Aug |
|
Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. | 2000 Aug 1 |
|
Activities of masked 2',3'-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. | 2000 Jan |
|
Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy. | 2000 Jun 16 |
|
Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report. | 2000 Sep |
|
Synthesis and antiviral activity of C-5 substituted beta-D- and beta-L-D4T analogues. | 2000 Sep |
|
Synthesis and biological evaluation of L- and D-configuration 1,3-dioxolane 5-azacytosine and 6-azathymine nucleosides. | 2000 Sep 18 |
|
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study. | 2000 Sep 29 |
|
Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. | 2001 |
|
Macrocytosis in patients on stavudine. | 2001 |
|
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. | 2001 Apr |
|
ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. | 2001 Apr |
|
Gynecomastia associated with highly active antiretroviral therapy. | 2001 Apr |
|
Treatment of hyperlipidemia in HIV-infected patients. | 2001 Apr 1 |
|
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. | 2001 Apr 13 |
|
Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. | 2001 Apr 13 |
|
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | 2001 Apr 13 |
|
The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance. | 2001 Apr 27 |
|
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. | 2001 Aug 1 |
|
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine. | 2001 Aug 15 |
|
Bristol-Myers warns of AIDS drugs' use. | 2001 Feb |
|
Genetic risks of antiviral nucleoside analogues--a survey. | 2001 Feb |
|
Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy. | 2001 Feb 16 |
|
Gene mutations identified. | 2001 Jan |
|
Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. | 2001 Jan 26 |
|
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases. | 2001 Jan-Feb |
|
New developments in anti-HIV chemotherapy. | 2001 Jan-Feb |
|
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. | 2001 Jul |
|
Predictors of protease inhibitor-associated adverse events. | 2001 Jul |
|
Stavudine versus zidovudine and the development of lipodystrophy. | 2001 Jul 1 |
|
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. | 2001 Jul 27 |
|
Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. | 2001 Jul-Aug |
|
Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. | 2001 Jun |
|
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. | 2001 Jun |
|
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. | 2001 Jun 29 |
|
Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. | 2001 Jun 29 |
|
Peripheral neuropathy and antiretroviral drugs. | 2001 Mar |
|
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. | 2001 Mar 30 |
|
An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase. | 2001 May 1 |
|
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. | 2001 May 5 |
|
Warning for pregnant women on HIV therapy. | 2001 May-Jun |
|
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | 2001 Sep |
|
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. | 2001 Sep 14 |
Sample Use Guides
Adults: The recommended dose based on body weight is as follows:
40 mg twice daily for patients ≥60 kg.
30 mg twice daily for patients <60 kg.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:04:54 GMT 2025
by
admin
on
Wed Apr 02 07:04:54 GMT 2025
|
Record UNII |
BO9LE4QFZF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175462
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
NDF-RT |
N0000009947
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
NDF-RT |
N0000175459
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.3 (LAM/NEV/STA)
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
WHO-VATC |
QJ05AF04
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
ZERIT (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
NDF-RT |
N0000175459
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
WHO-VATC |
QJ05AR07
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
LIVERTOX |
NBK548694
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.4.2.1
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
NDF-RT |
N0000175459
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
WHO-ATC |
J05AR07
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
||
|
WHO-ATC |
J05AF04
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
759897
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
C1428
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
59763
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
163661
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
STAVUDINE
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
6775
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
STAVUDINE
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | Description: A white to almost white powder. Solubility: Soluble in water and sparingly soluble in ethanol (~750 g/l) TS. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Stavudine should be kept in a well-closed container, protected from light. Additional information: Stavudine may exhibit polymorphism. Definition: Stavudine contains not less than 97.0% and not more than 103.0% of C10H12N2O4, calculated with reference to the dried substance. | ||
|
2478
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
CC-53
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
BO9LE4QFZF
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
3056-17-5
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
100000089694
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
BO9LE4QFZF
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
63581
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
Stavudine
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
1620209
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
D018119
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
DTXSID1023819
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
18283
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
DB00649
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
SUB10642MIG
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL991
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | |||
|
m10199
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
7338
Created by
admin on Wed Apr 02 07:04:54 GMT 2025 , Edited by admin on Wed Apr 02 07:04:54 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
The in vitro MIC (50% inhibitory concentration [IC50]) of d4T-TP against HIV-1 has been found to be between 0.009 and 6 ?M, depending on the phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors.
MAJOR
|
||
|
METABOLITE -> PARENT |
MINOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
Water (2.5.12): maximum 0.5 per cent, determined on 0.500 g.
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
Amount Not Specified
INTERNATIONAL PHARMACOPEIA
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||